West Pharmaceutical Services, Inc.WSTNYSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +2.24% | +0.42% | +9.15% | +7.69% | +7.55% |
| Gross Profit Growth | -1.65% | +0.61% | +18.12% | +10.67% | +10.75% |
| EBITDA Growth | +0.19% | -8.27% | +17.39% | +5.70% | +1.90% |
| Operating Income Growth | +0.00% | +1.10% | +20.95% | +3.52% | -8.21% |
| Net Income Growth | -5.04% | -22.12% | +18.42% | +2.94% | +1.54% |
| EPS Growth | -3.24% | -21.02% | +19.74% | +3.74% | +2.23% |
| EPS Diluted Growth | -2.73% | -20.65% | +20.53% | +4.32% | +2.25% |
| Weighted Average Shares Growth | -1.48% | -1.36% | -0.96% | -0.69% | -0.96% |
| Weighted Average Shares Diluted Growth | -1.73% | -1.75% | -1.22% | -0.95% | -1.36% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -20.49% | +9.48% | +7.33% | +9.49% | +32.09% |
| Free Cash Flow Growth | -34.66% | +110.51% | +57.25% | +35.53% | +105.40% |
| Receivables Growth | +7.91% | +3.74% | +21.49% | +19.21% | +3.96% |
| Inventory Growth | -13.27% | -9.58% | +0.45% | +9.17% | +17.75% |
| Asset Growth | -4.86% | +0.44% | +13.28% | +11.72% | +17.20% |
| Book Value per Share Growth | -5.49% | +1.47% | +14.77% | +11.65% | +19.55% |
| Debt Growth | -2.17% | -1.11% | -2.38% | -2.36% | +6.22% |
| R&D Expense Growth | +0.54% | -7.39% | +9.14% | +10.32% | +17.84% |
| SG&A Expenses Growth | -5.22% | +1.50% | +15.54% | +25.40% | +24.85% |